Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 3:10:445.
doi: 10.3389/fonc.2020.00445. eCollection 2020.

Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation

Luca Ferrari  1 , Michele Carugno  1   2 , Carolina Mensi  2 , Angela Cecilia Pesatori  1   2
Affiliations
Review

Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation

Luca Ferrari et al. Front Oncol. .

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers in easily accessible samples (such as blood) for early diagnosis of MPM. In the last 10 years, epigenetic markers, such as DNA methylation and microRNAs (miRNAs), have gained popularity as possible early diagnostic and prognostic biomarkers in cancer research. The aim of this review is to provide a critical analysis of the current evidences on circulating epigenetic biomarkers for MPM and on their translational potential to the clinical practice for early diagnosis and for prognosis.

Keywords: DNA methylation; circulating biomarkers; epigenetics; mesothelioma; microRNA.

PubMed Disclaimer

References

    1. Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. (2015) 24:115–31. 10.1183/09059180.00007014 - DOI - PMC - PubMed
    1. Husain AN, Colby TV, Ordonez NG, Allen TC, Attanoos RL, Beasley MB, et al. . Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. (2018) 142:89–108. 10.5858/arpa.2017-0124-RA - DOI - PubMed
    1. Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Roe OD. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. (2015) 41:486–95. 10.1016/j.ctrv.2015.05.001 - DOI - PubMed
    1. Bille A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. (2016) 11:249–55. 10.1016/j.jtho.2015.10.003 - DOI - PMC - PubMed
    1. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, et al. . Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. (2009) 124:201–7. 10.1002/ijc.23874 - DOI - PubMed